Purified natural killer (NK) cells were obtained from mice with severe combined immune deficiency (SCID) t o ascertain their effect on hematopoiesis. When activated and propagated with recombinant human interleukin-2 (rhlL-2) in vitro,
SCID spleen cells maintained a phenotypic and lytic spectrum consistent with a pure population of activated NK cells. When added with syngeneic bone marrow cells (BMC) in soft agar, the activated NK cells could support hematopoietic growth in vitro without the addition of exogenous hematopoietic growth factors. However, when syngeneic BMC were added along with cytokines t o produce optimal growth conditions, the addition of NK cells was then inhibitory for hematopoietic colony formation. Antibodies t o interferon7 (1FN-y) partially reversed the inhibitory effects. Supernatants from the NK-cell cultures could also exert these effects on hematopoiesis, although t o a lesser extent. Analysis of the NK cell RNA demonstrated that activated NK cells express genes for hematopoietic growth factors such as granulocyte-ATURAL KILLER (NK) cells are lymphoid cells that N are responsible for mediating a variety of immunologic and homeostatic functions. NK cells have the ability to lyse certain transformed cell lines and virally infected cells in a non-major histocompatibility complex (MHC)-restricted manner.' However, NK cells are also reported to regulate B-cell function.* Additionally, NK cells have been shown to mediate the rejection of bone marrow allografts, but not solid tissue allografts, in lethally irradiated mice. 3 Because NK cells can reject incompatible bone marrow cells (BMC), it has been postulated that NKcells also play a role in the regulation of hematopoiesis.' The majority of previous studies on NK cells, using both in vitro and in vivo assays, have suggested that they primarily exert a negative However, there have also been reports demon-macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF), and IL-lp. The NK cells were also found t o express IFN7, transforming growth factor-pl (TGF-pl), and tumor necrosis factor-a (TNF-a) mRNA. Analysis of the NKcell supernatants using factor-dependent myeloid progenitor cell lines showed that the NK cells were producing G-CSF and growth-promoting activity that could not be attributed t o IL-1, IL-3, IL-4, IL-5, IL-6, GM-CSF, G-CSF, macrophage CSF (M-CSF), or stem cell factor. The transfer of activated NK cells with BMC into lethally irradiated syngeneic mice resulted in greater BMC engraftment in the recipients. Thus, these results using a pure population of activated NK cells indicate that when activated, these cells can produce a variety of growth factors for hematopoiesis and exert significant hematopoietic growth-promoting effects in vivo. This is a US government work. There are no restrictions on its use.
strating that purified recombinant human interleukin-2 (rhIL-2)-activated NK cells were capable of producing the hematopoietic growth factor, granulocyte-macrophage colony-stimulating factor (GM-CSF).8,9 A major problem in the reconciliation of these findings has been the difficulty in obtaining pure populations of NK cells to assay. NK cells constitute a relatively small percentage of lymphoid cells and NK-cell preparations often contain contaminating populations of T cells. Although NK cells are similar to T cells morphologically and share certain surface markers, murine NK cells are negative for the T-cell markers CD3, CD4, and CD8.l Additionally, the few markers that NK cells express have also been found on other cell types,1° which makes cell depletion experiments difficult to interret.^ We circumvented this problem by obtaining pure populations of NK cells through the use of mice with severe combined immune deficiency (SCID), which lack T or B cells, yet have normal NK cells and NK cell function." We report here that purified rhIL-2-activated NK cells obtained from SCID mice exhibit dual properties in the regulation of hematopoiesis in vitro. We find that activated NK cells can inhibit colony-forming unit-culture (CFU-c) formation when cultured with BMC and hematopoietic growth factors in soft agar assays. This inhibition is mediated at least in part by interferon-y (IFN-y). However, activated NK cells cultured with BMC under limiting conditions, in the absence of exogenous hematopoietic growth factors, could support the growth of hematopoietic colonies in vitro. We report here that NK cells are capable of producing a variety of factors that affect hematopoietic cell growth, including a potentially novel hematopoietic growth factor. Additionally, the adoptive transfer of these activated NK cells with BMC resulted in greater hematopoietic engraftment in lethally irradiated syngeneic recipients. Thus, NK cells do not function exclusively as inhibitors of hematopoiesis; their hematologic effects are bifunctional. It is possible that their functions might be exploitable in certain clinical settings.
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MATERIALS AND METHODS
BALB/cJ (H-2d/Hh-ld) and C.B-17 scidlscid (SCID, H-2d/Hh-ld) were obtained from the Animal Production Area, National Cancer Institute (NC1)-Frederick Cancer Research and Development Center (FCRDC), Frederick, MD. SCID mice were kept in specific pathogen-free conditions until use. Mice were used at 8 to 12 weeks of age. SCID mice were given neomycin sulfate (Biosol liquid; Upjohn, Kalamazoo, MI), 200 mg (1 mL), in 500 mL of tap water.
NK cells were prepared from the spleens of 6-to 8-week-old SCID mice in a procedure described previously.12 The spleen cell suspension was cultured in 500 U/mL of rhIL-2 (a gift from Hoffmann-LaRoche, Nutley, NJ) for 7 to 10 days before use. Cultures were fed every 4 to 5 days with 500 U/mL of rhIL-2 until use. For marker analysis, cultured cells were incubated with the appropriate primary antibodies, as previously described." The primary antibodies used were 2Cll (anti-CD3), anti-Lyt-2 (anti-CD8), anti-L3T4 (anti-CD4), 2.462 (anti-Fc receptor), 30-H12 (anti-Thyl.2), 8C5 (a marker on murine granulocyte^),'^ B220 (RA3-6B2), Mac-1, and 5E6 (a marker found on a subpopulation of NK cells).14 Anti-L3T4 and anti-Lyt-2 were obtained from Becton Dickinson (Mountain View, CA). The 2Cl1, 30-H12, 2.402, Mac-1, 8C5, and B220 antibodies were generous gifts from Dr James Kenny, Program Resources Inc/DynCorp, NCI-FCRDC. All primary antibodies were directly fluorescein isothiocyanate (F1TC)-labeled or biotin-conjugated. Cells were then fixed in 1% paraformaldehyde and analyzed on an EPICS 753 flow cytometer (Coulter, Hialeah, FL).
Spleen cells or BMC cells from mice were washed and resuspended in Iscove's modified Dulbec-CO'S medium (IMDM) with 10% fetal bovine serum, 1% L-glutamine, and antibiotics (complete IMDM). A quantity of 5 X lo4 BMC or 5 x 105 spleen cells were plated in 0.3% bactoagar (Difco Laboratories, Detroit, MI) in 35-mm Lux petri dishes (Miles Laboratories, Naperville, IL). Colony formation was stimulated in some cases with predetermined optimal doses of growth-promoting cytokines such as rhIL-2 (500 U/mL) and purified murine IL-3 (10 ng/mL) supplied by the Biological Response Modifiers Program repository and purified recombinant murine GM-CSF at 10 ng/mL (AMGEN, Thousand Oaks, CA). Plates were incubated at 37°C for 7 days. The plates were scored for colonies, where greater than 50 cells constituted a colony. The anti-mouse interferon (IFN-v) monoclonal antibody was a rat IgGl (Lee Biomolecular, San Diego, CA) used at a 1:lOO dilution. In bone marrow transplant (BMT) studies, one-third spleen equivalent was plated 7 days after BMC transfer.
Total cellular RNA was isolated from cell preparations by a single-step phenol/chloroform extraction procedure using RNAsol (Cinna Biotecx, Friendswood, TX) as reported e1~ewhere.l~ Total cytoplasmic RNA (10 pg per sample) was size-fractioned on a formaldehyde-denaturing 0.8% agarose gel and transferred to Nytran (Schleicher and Schuell, Keene, NH).
After W cross-linking (Stratalinker, Stratagene, LaJolla, CA), blots were hybridized in NyloHybe (Digene, Silver Spring, MD) to 32P-labeled cDNA probes prepared by random priming using a commercially available kit (Pharmacia, Piscataway, NJ). Hybridization was for 24 to 36 hours at 42°C. After hybridization, the blots were washed for 10 minutes at room temperature in 2X standard saline citrate (SSC) 0.1% sodium dodecyl sulfate (SDS), followed by a 20-minute wash at 65°C in 0.02X SSC, 0.01% SDS. After hybridization with one probe, the blots were stripped by placing in boiling 0.02X SSC, 0.01% SDS for 20 minutes. Blots were then placed in hybridization buffer for 1 to 2 hours and the next probe was added. All cDNA probes had a specific activity of 2 to 8 x Mice.
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cpm/pg and all hybridizations were performed with 1 x cpm/mL. Blots were exposed to Kodak X-OMAT x-ray film (Eastman Kodak, Rochester, NY) for 24 to 72 hours at -70°C.
One microgram of total cellular RNA was first transcribed with Moloney Leukemia Virus Reverse transcriptase (BRL, Gaithersburg, MD) in a 100-pL reaction for 15 minutes at 42°C according to the manufacturer's instructions. The reaction was then heated to 99°C for 5 minutes and then cooled to 5°C for 5 minutes. Polymerase chain reaction (PCR) was then performed using 2 U of Perkin-Elmer Taq polymerase (Norwalk, CT) and mouse IL-3 primers (Clontech, Palo Alto, CA) according to the manufacturers' recommendations for 30 cycles, with each cycle consisting of 1 minute at 94"C, 2 minutes at 55"C, and 3 minutes at 72°C. At the end of 30 cycles, the reaction was completed by incubating at 72°C for 7 minutes. Ten microliters of the reaction was then run on a 0.8% agarose gel, the gel then denatured for 20 minutes in 0.4N NaOH, 1.5 mol/L NaCl, neutralized for 20 minutes in 1 mol/L Tris, pH 7.4, 1 mol/L NaCI, and transferred to Nytran in 1OX SSC for 3 hours. The membrane was then hybridized to a 32P-labeled IL-3 cDNA as described above.
Murine IFN-y, IL-2, and IL-4 cDNAs were obtained from DNAX Research Institute (Palo Alto, CA); murine GM-CSF cDNA from Dr A.W. Burgess (Ludwig Institute, Victoria, Australia); murine granulocyte CSF (G-CSF) cDNA from Dr Shigekazu Nagata (Osaka Biosciences, Osaka, Japan); murine tumor necrosis factor-a (TNF-a) cDNA from Dr Anthony Cerami (Rockefeller University, New York, NY); murine IL-la cDNA from Dr Peter Lomedico (Hohann-LaRoche, Nutley, NJ); murine IL-lp from Dupont deNemours (Wilmington, DE); murine IL-3 and IL-6 cDNAs from Dr Stephen Clark (Genetics Institute, Cambridge, MA); murine IL-5 cDNA from the American Type Culture Collection (Rockville, MD); murine IL-7 cDNA from Dr Steven Gillis (Immunex, Seattle, WA); murine transforming growth factor-pl (TGF-PI) cDNA from Dr Rik Derynck (Genentech, South San Francisco, CA); mouse perforin cDNA from Dr KO Okumura (Juntendo University, Tokyo, Japan); human IL-2 receptor p-chain cDNA from Dr Warren Leonard (National Institute of Child Health and Human Development, Bethesda, MD); and murine IL-2 receptor a-chain cDNA from Dr Jim Miller (University of Chicago, Chicago, IL).
The hematopoietic progenitor cell lines 32D-CL.23 and 32D-CL.3 were developed in murine long-term bone marrow cultures. 16 The NFS/Nl.M6 (MC-6) cell line17 was provided by Dr Douglas Williams (Immunex). These cell lines are IL-3-dependent and were maintained in complete RPMI 1640 medium plus 20% WEHI-conditioned medium as a source of IL-3. Briefly, the cell lines were washed twice in serum-free RPMI 1640 media and pelleted by centrifugation. The cells were then resuspended in complete RPMI 1640 medium (5% fetal calf serum, glutamine, and penicillin/streptomycin) and plated at a density of 5,000 cells in 100 pL in 96-well microtiter plates (Costar, Cambridge, MA). Some wells also contained 25% NK cell supernatants, which were collected after the NK cells were in culture with IL-2 for 7 to 10 days. Recombinant murine IL-3 was purchased from Promega (Rockyhill, NJ), and recombinant murine IL-4 from Genzyme (Cambridge, MA). The cells were then incubated for 48 hours at 37T, 5% CO2, and pulsed with 1 FCi [3H]thymidine (TdR) (6.7 Ci/mmol; New England Nuclear, Boston, MA) for the last 6 hours. The plates were then harvested with a multiple sample harvester on a glass filter. Individual filters were placed in 2 mL of PCS scintillation fluid (Amersham, Arlington Heights, IL) and radioactivity was assessed by liquid scintillation counting.
Recipient mice were exposed to 13' Cs gamma irradiation source. BALB/c mice received PoZymerase chain reaction analysis. cDNA probes.
Cell lines.
Irradiation and pretreatment of mice.
For personal use only. on October 25, 2017. by guest www.bloodjournal.org From 800 cGy total irradiation. Mice in some groups received 2 x IO7 SCID NK cells that were in culture with rhlL-2 for 7 to 10 days. The NK cells were injected with 1 x 1oh BALB/c BMC intravenously. The mice then received 50.OOO rhlL-2 in 0.5 mL phosphatebuffered saline (PBS) intraperitoneally once a day for 3 days after BMC transfer. Mice in other groups either received BMC alone, BMC with rhlL-2, BMC with 2 x IO7 BALB/c spleen cells and rhlL-2. or irradiation alone. In groups receiving irradiated NK cells, the NK cells were exposed to 2.00 cGy 3 hours hefore transfer. After 7 days, a soft-agar colony assay was performed on the spleens of the recipients to determine hematopoietic progenitor cell content. For analysis of the peripheral hlood, blood was collected from mice via the lateral tail vein, using EDTA as an anticoagulant. Complete blood cell counts were performed with a Coulter counter (Hialeah, FL) and differential cell counts were performed by microscopic examination of Wright's stained peripheral blood smears (Met Path, Rockville, MD). All experiments consisted of three to four mice per group with a representative experiment being shown. Student's r-test was performed to determine whether the values differed significantly at the (/' < .Wl) level.
RESULTS
N K cells can be propagated in vitro-and maintain a homogeneous phenotype.
To obtain purc homogeneous populations of NK cells to assay, SCID mice were used.Ix SCID mice have a defect in their rccombinasc system and cannot successfully rearrange their T-cell rcceptor or Ig genes.Iy As a result, SCID mice have no dctcctable T or B cells; however, they have normal NK cells and NK-cell function." SCID spleen cells were cultured with rhIL-2 for 7 to 10 days. This has been demonstrated to produce a purc population of activated NK cells with respect to phenotype and function.'? Thc cells obtained in this manncr wcrc positive for classical NK markers such as Thy-l (present on activatcd NK c~l l s ) ,~ FcR, and SE6 (present on a subpopulation of NK cells)IJ (Fig 1) . The cclls wcrc also greater than 9S% positive for asialo GMI (data not shown). The cells wcrc negative for CD3, CD4, and CDX; thc macrophage marker, MAC-I; the granulocyte markcr, XCS: and thc B-cell marker, B220 ( Fig I) . Thcse cells also maintained a lytic spectrum consistent with a purc population o f activatcd NK cells (data not shown).'& The NK cells wcrc then used in a soft-agar hematopoietic colony formation assay to dcterminc thc role of these cells in hcmatopoicsis.
Activated NK cells can sripporr hemntopoiesis in 1.itt-o. When activatcd NK cells or BMC arc placed in soft agar alone, no hematopoietic colonies are formed (Table I) . Howcvcr, whcn activatcd NK cells arc addcd with the RMC at a 1:l ratio, hcmatopoictic colonics appeared. Additionally, culture supernatants obtained from the propagated NK cells could also support the growth of BMC, although to a much lesser extent. Howcvcr, the addition of rhlL-2 alone had no cffcct on colony formation. Phenotypic analysis of the colonies indicated that they wcrc of myeloid origin, consisting of macrophage, granulocyte, and granulocyte/ macrophage-type colonies. Intcrcstingly, whcn NK cells wcre addcd together with BMC and CSFs such as IL-3 and GM-CSF, a significant dcgrcc of inhibition (62%) of colony growth was observed (Table I) . Thus, NK cells appear to be bidircctional regulators of hematopoiesis: whcn given alone with BMC, they can promote colony formation, but they can a . Data representative of four experiments. *Cultures were supplemented with IL-3 (10 nglmL) and GM-CSF (10 nglmL), rhlL-2 (500 UlmL), NK-cell supernatant (0.2 mL); or 7 to 10-day rhlL-2-cultured SClD spleen cells containing at least 95% NK cells were plated at a 1:l ratio with BMC (2 x 105) in 100 pL rhlL-2-containing media (500 UlmL).
tSClD BMC were plated in soft agar according to the procedure described in Materials and Methods. The plates were scored for colony growth after 7 days. also inhibit hematopoietic cell growth driven by exogenously added hematopoietic growth factors.
NK cells transcribegenes fora variety of cytokines capable of exerring diverse effects on hematopoiesis.
To determine what cytokines activated NK cells were capable of producing, we first examined mRNA expression. As shown in Fig  2, mRNA for a number of different cytokine genes was detected when total cellular RNA from the rhIL-2activated NK cells was analyzed. Specific hybridization was observed with probes for IL-lp, IL-6, G-CSF, GM-CSF, TNF-a, IFN-y, TGF-P1, and both the rhlL-2 receptor aand P-chains (Fig 2) , as well as perforin, a protein involved in cell killing (data not shown). In contrast, no hybridization was observed with probes for IL-la, IL-2, IL-3, IL-4, IL-5, or M-CSF (data not shown). To be certain that IL-3 mRNA was not present at levels below the threshold of detection, amplification of IL-3 mRNA was attempted by PCR analysis. No IL-3 mRNA was detected (Fig 3) , even though it was found when examining rhIL-2-activated splenocytes from 
Supematants from NK-cell cultures support the growth of factor-dependent hematopoietic progenitor cell lines and ahibit potentially novel growth factor activiy.
To determine what factors were present in the conditioned medium obtained from the cultured IL-2-stimulated NK cells, supernatants were examined for growth-promoting activity on factor-dependent myeloid cell lines. A description of the factors to which the different cell lines respond is given in Table 2 . NK-cell supernatants induced the proliferation of 32D-CL.23 and 32D-CL.3 cell lines, but not MC-6 ( Table 3) and FDC-P1 lines (data not shown) as measured by
[3H]TdR incorporation. In agreement with PCR and Northern blot data, the supernatants did not contain IL-3 or IL-4 activity, as indicated by the lack of proliferation induced on MC-6 and FDC-P1 cell lines. Additionally, because the supernatants do not contain IL-3 and yet promote the growth of 32D-CL.3 cells, this suggests that the supernatants contain G-CSF. No neutralizing antibody to murine G-CSF is available to confirm this result, although such a conclusion is also in agreement with the Northern blot analysis, which demonstrates that activated NK cells produce G-CSF mRNA (Fig 2) . Interestingly, the NK-cell supernatants also induced the proliferation of 32D-CL. 23 , which have been reported to respond to IL-3 or IL-4, but not to other CSFs. 16 In addition, antibodies to IL-3 and IL-4 did not block the proliferation of 32D-CL.23 induced by the 
NK-cell supernatants, suggesting that the proliferation was not due to IL-3 or IL-4 (data not shown). This is also in agreement with the lack of an effect of the supernatants on MC-6 cell line proliferation, which would detect the presence of IL-3 or IL-4. The lack of proliferation of MC-6 cells in response to the supernatants also indicates that the NK cells are not producing the c-kit ligand or stem cell factor (SCF). Thus, taken together, these results suggest that there may be a novel hematopoietic growth factor produced by the NK cells responsible for the proliferation of the 32D-CL.23 cell line. Analysis of various other cloned growth factors (IL-1, GM-CSF, G-CSF, TNF) also failed to induce the proliferation of 32D-CL.23, when either given alone or in combination (data not shown). Further experiments will be required to determine the nature of this activity to ascertain if it is due to a novel growth factor produced by the NK cells.
Activated NK cells produce IFN-y, which can inhibit hematopoiesis in vitro.
Northern blot analysis had indicated that NK cells could produce IFN-y, and we wanted to determine if this was responsible for the hematopoietic suppression seen in vitro. Previous reports have also indicated that NK cells can produce IFN-y, which can be inhibitory for hematopoiesis.4 Therefore, to examine whether IFN-y could be contributing to colony growth inhibition when NK cells were placed with BMC in the absence of exogenous cytokines, antibodies to IFN-y were added with NK cells and BMC. The addition of this neutralizing antibody resulted in an 87% increase in colony formation ( Table 4 ). The presence of IFN-y antibodies also significantly increased colony formation supported by the NK-cell supernatants. Additionally, the antibodies to IFN-y could abrogate the NK cell-mediated inhibition of colony formation when the BMC were placed with IG3 and GM-CSF. NK cells plated in agar with either exogenous hematopoietic growth factors or with anti-IFN-y did not give rise to colony formation. Thus, activated NK cells can produce hematopoietic growth factors that support BMC growth in vitro and their effect can be enhanced through the neutralization of inhibitory cytokines, such as IFN-y, which are also produced. Protein analysis of the supernatants using various bioassays also demonstrated the presence of IL-lB, IL-6, and IFN-y (data not shown). The presence of TGF-p was not assayed for at the present time. Thus, although NK cells can produce factors that are inhibitory for hematopoiesis, the demonstration that when NK cells are placed with BMC alone they can support BMC growth suggests that the factors they produce which promote hematopoiesis may, under the appropriate conditions, provide a stronger net stimulus.
rhll-2-activated NK cells can be adoptively transferred and promote engraftment of syngeneic BMC in lethally irradiated recipients. Because the NK cells were shown to be capable of supporting hematopoiesis in vitro, we wanted to determine if these properties could also be transferred in vivo using a syngeneic BMT model. BALB/c mice were lethally irradiated and given syngeneic BMC with or without activated SCID NKcells. The results ( 1, 190 Results are representative of three experiments and are the mean 2 SE of three determinations. Abbreviation: CPM, counts per minute. 'Cell proliferation was determined by [3H] Tdr incorporation as described in Materials and Methods. tNK cell-conditioned medium was obtained after SClD spleen cells were cultured with 500 U/mL rhlL-2 for 7 to 10 days. The phenotype of cells SIL-3 and IL-4 were used at a concentration of 20 ng/mL and the NK-cell supernatent was used at 25% in the proliferation assays.
present was greater than 95% NK cells as determined by flow cytometry.
in an enhancement of marrow engraftment as determined by growth in soft agar when the spleens of the mice were analyzed 7 days after BMC transfer. However, the transfer of rhIL-2-activated NK cells with BMC resulted in significantly (P < .001) greater colony formation in the recipients when compared with mice receiving BMC alone or in combination with rhIL-2. Therefore, the transfer of rhIL-2activated NK cells with BMC can aid in marrow engraftment after syngeneic BMT. We then wanted to determine if this effect on marrow engraftment was dependent specifically on the transfer of activated NK cells. In another experiment, BALB/c splenocytes and rhIL-2 were transferred with BMC. The transfer of splenocytes plus IL-2 did minimally enhance colony formation in the recipients, but not to the extent of the groups receiving NK cells and rhIL-2 (Table 6 ). Indeed, the effects of IL-2 plus normal spleen were not significantly greater than the effects of IL-2 alone. Additionally, the transfer of irradiated NK cells failed to improve engraftment, indicating that the NK cells were not passively affecting the BMC by altering the pattern of stem cell homing to the spleen. The recipients receiving only NK cells with rhIL-2 and no BMC did not demonstrate significant hematopoietic engraftment and the mice died within a time frame comparable to the mice tSClD BMC were plated in soft agar according to the procedures described in Materials and Methods and scored for colony growth after 7 days. receiving radiation alone. These data demonstrate that cultured SCID NK cells do not themselves have the potential to give rise to hematopoietic cells in mice. Analysis of the peripheral blood indicated that the transfer of activated NK cells with BMC significantly improved platelet counts by day 9, resulting in an almost threefold increase in platelets (Fig 4) . No other hematologic parameters were significantly affected at this time, although hematocrit values were also slightly elevated when compared with groups receiving BMC alone (data not shown). Taken together, these results support the notion that transfer of activated NK cells promotes hematopoietic engraftment and improves hematologic parameters after syngeneic BMT in mice.
DISCUSSION
The data presented here indicate that activated NK cells exhibit a dual role in their hematopoietic regulatory abilities based on their ability to produce a wide range of cytokines (GM-CSF, G-CSF, IL-1P, TNF-a, IFN-y, and TGF-P). When BMC are placed under optimal growth conditions (ie, with exogenous cytokines such as IL-3 and GM-CSF), the addition of activated NK cells does indeed inhibit colony formation, as has been demonstrated by However, when BMC are placed in agar under limiting conditions, the addition of activated NK cells promotes CFU-C formation to a significant extent. Thus, the failure of other investigators to detect hematopoietic growth-promoting factors produced by NK cells was per- Data are representative of three experiments with three to four mice 'IL-3 and GM-CSF were added with spleen cells 7 days after tFiftythousand units of rhlL-2 given intraperitoneally days 0,l. and 2.
*Two x 107 SClD NK cells given with BMC intravenously on day 0, §Values significantly (P < .001) greater than recipients receiving per group.
irradiation as described in Materials and Methods. and 50,000 U rhlL-2 given intraperitoneally on days 0,1, and 2.
either BMC or BMC with rhlL-2.
For personal use only. on October 25, 2017. by guest www.bloodjournal.org From concerning their effect on hematopoietic growth. Additionally, by using only pure NK cells obtained from SCID mice, one can more stringently examine NK-cell properties without putting them through extensive and possibly incomplete purification procedures.
We have demonstrated that activated NK cells are capable of secreting a wide array of both hematopoietic growth-promoting (IL-1P, G-CSF, GM-CSF) and -inhibiting cytokines (IFN-y, TGF-P, TNF-or), as well as a potentially novel hematopoietic growth factor. More work needs to be performed to characterize this new activity. In our studies, we examined whole populations of SCID NK cells. However, subpopulations of NK cells may exist that exert primarily growth-promoting versus growth-inhibiting functions on hematopoiesis based on the cytokines that they produce. Preliminary results suggest that different subsets of NK cells that exert different regulatory effects on hematopoiesis do exist in mice. Isolation of NK-cell subpopulations that solely promote hematopoietic growth may also allow for easier isolation and characterization of the potentially novel hematopoietic growth factor(s) they may produce.
It is of interest that G-CSF has not been previously described to be produced by NK c e k 8 Human NK-cell populations were examined in many of these studies suggesting that either G-CSF is only produced by murine NK cells or, since human NK cells can be heterogenous with regard to cell-specific markers, subpopulations of NK cells may have been unknowingly excluded in those studies.
Studies using T-cell-depleted bone marrow to reconstitute human hematopoiesis have suggested that T cells are involved in promoting hematopoiesis. The recent characterization of an immunodeficiency disease which resulted from the inability of the patient's T cells to transcribe genes for rhIL-2, IL-3, IL-4, IL-5, and IFN-y suggests that other cell types may contribute to the maintenance of normal hematopoiesis, since the patient's hematologic parameters appeared normaLZ0 It is possible that, under certain circumstances, NK cells may be involved. For example, the SCID mouse completely lacks T cells, is profoundly deficient in lymphopoiesis, but is normal in NK-cell function; despite its immunologic dysfunction, the SCID mouse exhibits normal hematopoiesis?1
The demonstration that activated NK cells can support hematopoiesis in vivo also suggests that they may be of clinical use to promote hematopoietic engraftment after BMT. The clinically available CSFs have been shown to promote erythropoiesis (erythropoietin) and granulopoiesis (G-CSF, GM-CSF), but none has consistently promoted thrombopoiesis. Our animal data suggesting that activated NK cells may enhance platelet recovery merit testing this approach in humans. Later time point analysis indicates that mice receiving NK cells and rhIL-2 also had accelerated immune reconstitution. 22 This result also suggests that the transfer of activated NK cells with rhIL-2 may be able to enhance antitumor effects when autologous BMT is used in the treatment of neoplasia. We have recently found that the transfer of donor-type activated NK cells with BMC into lethally irradiated allogeneic mice also resulted in better For personal use only. on October 25, 2017. by guest www.bloodjournal.org From IL-2-ACTIVATED NATURAL KILLER CELLS 677 marrow engraftment and long-term donor-derived immune reconstitution. 22 The idea that NK cells may be stimulatory for marrow growth is also supported by recent data using a rat model in which rhIL-2-activated NK cells supported the growth of syngeneic BMC, but inhibited allogeneic BMC growth in vitro.23 Therefore, the transfer of donor-type rhIL-2-activated NK cells after BMT may be able to provide the positive graft-versus-leukemia effects without giving rise to graft-versus-host disease in recipients."
Thus, activated NK cells are capable of producing a variety of hematopoietic growth factors, including a potentially novel cytokine, and can be adoptively transferred to promote the engraftment of syngeneic BMC in vivo. Furthermore, the data presented here suggest that activated NK cells may be of considerable use clinically to promote hematopoiesis.
